GLAXOSMITHKLINE: The return in oncology further accelerates through a deal with Merck KGaA | NEUTRAL | 1660p
GLAXOSMITHKLINE - NEUTRAL | 1660p(+9%)The return in oncology further accelerates through a deal with Merck KGaA
After Tesaro comes an ambitious agreement with Merck KGaA
Could GSK and Merck KGaA become leaders in IO?
A deal worth up to EUR3.7bn (GBP3.2bn)
GlaxoSmithKline is a global healthcare company. Co.'s segments include: Pharmaceuticals; Vaccines; and Consumer Healthcare. The Pharmaceuticals segment is focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation, with discovery research exploring these and other areas. The Vaccines segment has a portfolio and pipeline of vaccines to help protect people throughout life. Co. delivers vaccines to people living in over 160 countries. The Consumer Healthcare segment develops and markets consumer-preferred brands in oral health, pain relief, respiratory, nutrition/gastro-intestinal and skin health.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.